Any person who may contribute to the content of this continuing education activity must disclose relevant relationships (and any known relationships of their spouse/partner) with commercial interests whose products or services are discussed in educational presentations. A commercial interest is defined as an entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on patients. Relevant relationships include receiving from a commercial interest research grants, consultant fees, travel, other benefits, or having a self-managed equity interest in a company.

Disclosure of a relationship is not intended to suggest or condone any bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation.

Planners:

Adrienne Matson, PharmD, BCPS – has no relevant financial relationships to disclose in relation to the content of this activity.
Katie Richardson, PharmD, BCOP – has no relevant financial relationships to disclose in relation to the content of this activity.
Victoria Sherry, DNP, CRNP, ANP-BC, AOCNP – has no relevant financial relationships to disclose in relation to the content of this activity.
Van Anh Trinh, PharmD, BCOP – has no relevant financial relationships to disclose in relation to the content of this activity.
Jeffrey S. Weber, MD, PhD – has disclosed that he is a consultant for Bristol-Myers Squibb, Merck, AstraZeneca, EMD Serono, Genentech, Amgen, Incyte, GlaxoSmithKline, Windmill, Celldex, CytoMx, and Sellas; his institution receives grant/research support from Bristol-Myers Squibb, Merck, AstraZeneca, EMD Serono, GlaxoSmithKline and Incyte.

Authors/Presenters:

Sanjiv S. Agarwala, MD - has no relevant financial relationships to disclose in relation to the content of this activity.
Scott J. Antonia, MD, PhD - has disclosed that he is on the advisory board for AstraZeneca, Boehringer Ingelheim, Bristol-Meyers Squibb, Genentech, Memgen, and Novartis; he does contracted research for Novartis, is on the scientific advisory committee for CBMG, and is the founder of Nilogen Oncosystems.
Michael B. Atkins, MD - has disclosed that he is a consultant for Bristol-Myers Squibb, Merck, Novartis, Pfizer, Genentech, Nektar Therapeutics, Celldex Therapeutics, Aduro Biotech, and Idera; his institution receives grant/research support from Pfizer and Bristol-Myers Squibb.
Joshua Bauml, MD - has disclosed that he is a consultant for AstraZeneca, BMS, Boehringer Ingleheim, Celgene, Clovis, Genentech, Guardant Health, and Merck; his institution receives grant/research support from Bayer, Carevive Systems, Clovis, Janssen, Merck, and Novartis.
Edward B. Garon, MD – has disclosed that he is a consultant for AstraZeneca, Bristol-Myers Squibb, Genentech, Merck, Eli Lilly, Mirati, and Pfizer.
David E. Gerber, MD – has disclosed that he receives research funding from ArQule, Boehringer-Ingelheim, BerGenBio, Celgene, Genentech, ImmunoGen, Karyopharm, and Peregrine. He is on advisory boards for AstraZeneca, Boehringer-Ingelheim, Bristol-Myers Squibb Company, Celgene, Genentech, Guarant, MS, Peregrine, Samsung, and Synta.
Geoffrey Gibney, MD – has disclosed that he is a consultant for Boston Biomedical, Genentech, Incyte, and Novartis; he is on the speaker's bureau for Genentech and Merck.
Leora Horn, MD MSc – has disclosed that she is a consultant for AbbVie, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Genentech, Janssen, Merck, and Xcovery.
Anna C. Pavlick, DO – has disclosed that she is a consultant for Bristol Myers Squibb, Merck, Novartis, and Seattle Genetics.
Victoria Sherry, DNP, CRNP, ANP-BC, AOCNP– has no relevant financial relationships to disclose in relation to the content of this activity.
Tom Stinchcombe, MD – has disclosed that he is a consultant for AstraZeneca, Novartis and Takeda. His institution receives grant/research support from Genentech and Merck.
Van Anh Trinh, PharmD, BCOP – has no relevant financial relationships to disclose in relation to the content of this activity.
Jeffrey S. Weber, MD, PhD – has disclosed that he is a consultant for Bristol-Myers Squibb, Merck, AstraZeneca, EMD Serono, Genentech, Amgen, Incyte, GlaxoSmithKline, Windmill, Celldex, CytoMx, and Sellas; his institution receives grant/research support from Bristol-Myers Squibb, Merck, AstraZeneca, EMD Serono, GlaxoSmithKline and Incyte.
Matthew R. Zibelman, MD - has disclosed that he is on the advisory board for EMD-Serono; his institution receives grant/research support from BMS and Horizon Pharmaceuticals.

Reviewers:

Sanjiv S. Agarwala, MD - has no relevant financial relationships to disclose in relation to the content of this activity.
RuthAnn Gordon, MSN, FNP-BC, RN, OCN - has no relevant financial relationships to disclose in relation to the content of this activity.
Josiah D. Land, PharmD, BCOP - has no relevant financial relationships to disclose in relation to the content of this activity.